Home → Focus

Focus Launches Its Healthcare Marketplace to Make the Affordable Care Act (ACA) More Affordable for Consumers Print E-mail
Written by FHInews   
Wednesday, 05 September 2018 00:00

FORT LAUDERDALE (September 5, 2018) -- MediXall Group Inc., (OTCQB: MDXL), a technology and innovation-driven organization structured to bring effective change to the U.S. healthcare industry, is pleased to announce today that the company has launched to uninsured and high-deductible consumers throughout the state of Florida. This first full-featured platform launch will focus on Radiology Full Diagnostics, which includes MRI, CT, PET, X-rays, ultrasound, mammogram scans and more. will subsequently be rolling out an extended list of in-demand medical and dental specialties in the near future.

Radiology diagnostic imaging centers became the initial specialty for the full launch because MediXall’s research indicated this sector of the healthcare industry suffers the most serious pricing discrepancies, thus, acutely in need of a pricing transparency intervention. In Florida, prices for MRIs, PET scans, CT scans, X-Rays and other diagnostic imaging services can vary widely, within a town, or county—without necessarily any real difference in the quality of outcomes as well. For example, MRI costs can range from $400 to over $3000 for the same service within South Florida. In addition, increasing numbers of patients go without insurance entirely, thinking their healthcare needs would not justify the expense of an insurance premium. According to the National Center for Health Statistics, over 48% of this state’s population between the age of 18 to 64 in 2017 was reported to be uninsured, or struggling with a high deductible insurance policy, leaving patients paying cash for medical imaging services that they cannot evaluate or comparison-shop, due to lack of available information.

The company’s initial diagnostic imaging focus was exponentially accelerated by a partnership with CoreChoice, Inc., the nation’s leading specialty network for diagnostic radiology, neurodiagnostic testing, and interventional pain management, which exists to increase consumer access to high-quality and low-cost services for the self-pay and underinsured market across the country. With over 22,000 radiology providers and facilities in the CoreChoice network, the partnership will create one of the nation’s largest networks of affordable, high quality providers – offering consumers an unprecedented opportunity to compare radiology service providers across the country based on a best all-in cash price, location/distance, ratings, & availability, and select the best value according to personal preferences

With this launch, the Company is also adding the Referral Program as a tool for physicians to share the cost and location information. By launching and the associated Referral program, the platform will now provide a one-stop-shop for patients and referring physicians to search, compare, and book most diagnostic/imaging services. Through this innovative toolkit, healthcare providers can decrease patients’ out-of-pocket expenses, streamline referrals, and improve the patient-physician relationship by facilitating a transparent conversation about cost and value.

“We learned many things over the last few months with the controlled launch of that allowed us to perfect the way the platform serves our customers. Taking the time to do this extra step allowed the development team to focus on optimizing the interface and functionality to improve the healthcare shopping experience for our users,” said MediXall President Michael Swartz.  “With these improvements, I believe consumers will find extremely simple to use, since it now works much like booking a hotel or flight through Priceline or a similar online booking site, providing consumers with user-reviews, transparent pricing, and comparative shopping.”

About is a new generation healthcare marketplace platform designed to address the growing need of self-pay and high deductible consumers for greater transparency and price competition in their healthcare costs. With MediXall, consumers now have the option to search for doctors or dentists and book appointments based on cost, distance, ratings, and availability at the click of a button.  By delivering a solution that better connects consumers with high-quality healthcare providers and wellness services, enables healthcare providers to engage consumers with a level of price transparency and digital convenience that they have come to expect in every other aspect of their lives. In this era of rapidly increasing deductibles and healthcare costs, the cloud-based platform is designed to be transformational and disruptive to traditional methods of medical care and provisioning of medical services to the consumer. For more information, please visit or call (954) 440-4678.

About MediXall Group, Inc.
MediXall Group is a technology and innovation-driven organization purposefully designed and structured to bring effective change to the U.S. healthcare industry that is actively trading on the OTCQB under the symbol “MDXL.” The Company believes its revolutionary approach will help drive much-needed change that it envisions is needed in the current healthcare system. The mission of the MediXall Group is to revolutionize the medical industry by improving communication; providing better technology and support services; and enabling more efficient, cost-effective healthcare for the consumer. By approaching the healthcare ecosystem as a whole, MediXall creates, invests and incubates companies that embody its mission statement.

Safe Harbor Statement
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the Company’s current plans and expectations, as well as future results of operations and financial condition. Specifically, the Company’s ability to raise additional capital, execute its business plan and strategy, sustain or increase gross margins, achieve profitability and build shareholder value are forward looking statements. A more extensive listing of risks and factors that may affect the Company’s business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the Company with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Media Contact Information:
Kip Hunter Marketing - 954-765-1329
Nicole Lewis

Last Updated on Friday, 21 September 2018 10:45
What Have We Learned About Bundling Medical Conditions? Print E-mail
Written by FHI's Week in Review   
Monday, 03 September 2018 15:13
In an Aug. 28, 2018 Health Affairs blog post we get an insightful update from authors Amol S. Navathe, Eric Shan, and Joshua M. Liao:
...the impact of bundled payments appears to differ between surgical and medical episodes. On one hand, Medicare has achieved promising results from bundling surgical care for lower extremity joint replacement...On the other hand, recent evidence corroborates analyses conducted by Medicare and its contractor, suggesting that as designed, bundles for medical conditions such as congestive heart failure (CHF) and chronic obstructive pulmonary disease (COPD) are not associated with significant changes in quality or Medicare spending.
Read more in the current issue of Week in Review>>
Last Updated on Monday, 03 September 2018 15:24
Hospitals battle for control of lucrative heart valve procedure Print E-mail
Written by Phil Galewitz | KHN   
Friday, 24 August 2018 17:04
When Medicare in 2011 agreed to pay for a revolutionary procedure to replace leaky heart valves by snaking a synthetic replacement up through blood vessels, the goal was to offer relief to the tens of thousands of  patients too frail to endure open-heart surgery, the gold standard. To help ensure good results, federal officials limited Medicare payment only to hospitals that serve large numbers of cardiac patients. The strategy worked. In the past seven years, more than 135,000 mostly elderly patients have undergone transcatheter aortic valve replacement, known as TAVR. And TAVR's in-hospital mortality rate has dropped by two-thirds, to 1.5 percent.  
Now, in a campaign motivated by a muddy mix of health care and business, smaller hospitals and the medical device industry are arguing that  the technique should be more widely deployed. They note only about half of the nearly 1,100 hospitals offering surgical valve replacement can do TAVR. And they say current limitations discriminate against minorities and people in rural areas, forcing patients to undergo a riskier and significantly more invasive treatment - or miss getting a new valve altogether.
Last Updated on Friday, 07 September 2018 06:56
Trump urges Sessions to bring federal suit against opioid makers Print E-mail
Written by FHI's Week in Review   
Monday, 20 August 2018 00:00
Jordan Fabian and Nathaniel Weixel report for on 08/16/18:
President Trump on Thursday urged Attorney General Jeff Sessions to bring a federal lawsuit against drug companies that produce opioids. Speaking during a Cabinet meeting, the president also asked his embattled attorney general to look at opioid drugs coming into the country from China and Mexico, saying those countries were "sending their garbage and killing our people."
Read more in the current issue of Week in Review>>
Last Updated on Tuesday, 21 August 2018 07:05
Jury Awards $289M to Man Who Blames Roundup for Cancer Print E-mail
Written by FHI's Week in Review   
Monday, 13 August 2018 16:51
AP, via, informs us that Dewayne Johnson, 46, alleged that heavy contact with the herbicide Roundup caused his non-Hodgkin's lymphoma. On August 10 the California Superior Court jury agreed that Roundup contributed to Johnson's cancer and Monsanto, the manufacturer of the herbicide, should have provided a label warning of the potential health hazard. Monsanto has denied a link between the active ingredient in Roundup - glyphosate - and cancer, saying hundreds of studies have established that glyphosate is safe.
Read more in the current issue of Week in Review>>
Last Updated on Tuesday, 04 September 2018 16:58
<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>

Page 5 of 129

Website design, development, and hosting provided by